Patient Reported Outcome in metastatic breast cancer and platinum-resistant recurrent ovarian cancer treated with metronomic cyclophosphamide ± methotrexate: PROmetronomic - FoR.UM 19-02193

Purpose In the treatment of both metastatic breast cancer (MBC) and platinum-resistant recurrent ovarian cancer (ROC), symptom control and maintenance of quality of life (QoL) play a crucial role. In the advanced stage of disease, metronomic chemotherapy (MCT) may be a favourable treatment option. The aim of this study is to assess the QoL of heavily pretreated patients with MBC and ROC treated with MCT.

Methods PROmetronomic is a monocentric, open-label, single-arm observational study to assess health-related patient-reported outcome data in MBC and ROC treated with MCT (cyclophosphamide 50 mg daily ± methotrexate 2.5 mg every other day). QoL data, symptoms and adverse events are evaluated using EORTC QLQ-C30 version 3.0, EORTC QLQ-BR23 version 1.0 (MBC)/EORTC QLQ-OV28 version 1.0 (ROC) questionnaires and HADS-D in the CANKADO programme. Patients previously treated with at least 2 lines of endocrine therapy (for hormone receptor-positive cancer) and at least 2 lines of chemotherapy (MBC)/at least 1 line of platinum-based and 1 platinum-free chemotherapy (ROC) are included. Secondary endpoints are disease control rate at 12 and 24 weeks, progression-free survival and overall survival.

Results Until 2021-02-28, 3 MBC and 3 ROC patients have been enrolled. It is planned to include a total of 65 patients until 08/2023.

Conclusions Potentially toxic chemotherapy is often required to achieve disease control in patients with metastatic cancer. However, well-being and personal preferences must not be neglected. MCT could provide an efficacious treatment option with limited toxicities and positive impact on QoL.

Interessenkonflikt

Es bestehen keine Interessenkonflikte.

Publication History

Article published online:
01 June 2021